Periprocedural antithrombotic management.
10.5124/jkma.2014.57.5.419
- Author:
Jin JOO
1
Author Information
1. Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. jiyo1004@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Antithrombotic therapy;
Antiplatelet therapy;
Bridging therapy;
Heparin;
Vitamin K antagonist
- MeSH:
Anticoagulants;
Hemorrhage;
Heparin;
Humans;
Vitamin K
- From:Journal of the Korean Medical Association
2014;57(5):419-426
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The periprocedural management of patients on long-term antithrombotic therapy (antiplatelet agents or vitamin K antagonists) who may require temporary disruption, given that an invasive procedure is always a dilemma for clinicians. Discontinuation of antithrombotic therapy can place patients at an increased risk of thromboembolic complications while the continuation of antithrombotic therapy can increase the procedure-related bleeding risk. Therefore, it is imperative for clinicians to be proficient in making thoughtful and individualized decisions on the appropriate management of periprocedural anticoagulants, drawing from recent evidence-based guidelines.
